Kornimate/medical-research-clean huggingface dataset:
metabolic phenotyping during stress hyperglycemia in cardiac surgery patients

Conditions: Stress Hyperglycemia

Summary: this study is a prospective randomized study to examine the effects of exposure to dulaglutide on the prevention of stress-hyperglycemia and the metabolic inflammatory response in the perioperative period.

stress hyperglycemia is common in the perioperative period and is associated with increased risk of death postoperatively. counterregulatory hormones and inflammatory mediators appear to modulate the acute biological response to stress, however, the pathophysiological pathways that result in stress hyperglycemia and its link to poor clinical outcomes are not well understood. at least half of non-diabetes mellitus (dm) patients undergoing cardiac surgery develop stress hyperglycemia shown to be an independent risk factor of morbidity and mortality. the current approach to treat hyperglycemia with insulin has major limitations including high resource utilization and high risk of hypoglycemia. the main goals of this study are to examine baseline and postoperative metabolic profiles of non-diabetic, coronary artery bypass grafting (cabg) patients with stress hyperglycemia and to study the effect of a long-acting glucagon-like peptide-1 receptor agonists (glp-1 ra) on the prevention of stress-hyperglycemia and modulation of metabolic stress during cardiac surgery. to examine whether exposure to dulaglutide, a glp-1 ra, can improve glycemic control and ameliorate the inflammatory response to acute surgical stress, obese patients without diabetes mellitus undergoing cabg surgery will be randomized to receive either dulaglutide or placebo two to three days prior to surgery. the researchers of this study ultimately want to provide evidence to support the use of novel therapies to prevent and manage stress hyperglycemia in the inpatient setting.

Eligibility criteria:
inclusion criteria: * males or females between the ages of 40 and 80 years * body mass index (bmi) ≥25 * undergoing elective cabg surgery * no previous history of diabetes or hyperglycemia exclusion criteria: * hyperglycemia (bg\>125 mg/dl or hba1c \> 6.5%) or previous treatment with antidiabetic agents * impaired renal function (gfr \< 30 ml/min) or clinically significant hepatic failure * gastrointestinal obstruction expected to require gastrointestinal suction * patients with clinically relevant pancreatic or gallbladder disease * treatment with oral or injectable corticosteroid * mental condition rendering the subject unable to understand the possible consequences of the study * pregnancy or breastfeeding at time of enrollment

Keywords: coronary artery bypass surgery (cabg) post operative obesity
a study to evaluate the effects of tyramine in patients who completed the presto study.

Conditions: Parkinson's Disease

Summary: this study is to determine if tyramine has any side effects on patients receiving 0.5mg, 1mg of rasagiline or placebo


Eligibility criteria:
inclusion criteria: men and women with idiopathic parkinson's disease (pd) who have met inclusion criteria for presto, and have completed the 26-week presto study. the subject should be available to participate in the sub-study immediately following the last presto visit (same day). subjects must continue presto study drug until the morning of the tyramine sub-study. subjects must provide separate informed consent to participate in the tyramine sub-study. exclusion criteria: subjects must not have a history of intracranial aneurysm or stroke. subjects should not have uncontrolled hypertension, defined as systolic pressure \> 160 mmhg, or diastolic pressure \> 90 mmhg.
health behavior change in midlife adults at risk for alzheimer's disease

Conditions: Alzheimer Disease

Summary: modifying health behaviors like physical activity level, diet, stress, and mental activity level can lower risk for alzheimer's disease, but many middle-aged and older adults find it difficult to sustain health behavior changes over the long term. this project will develop a new intervention that educates people about alzheimer's disease risk factors and helps them understand how their personal health beliefs may prevent them from making long-lasting lifestyle changes. the goal is to help people sustain health behavior changes to prevent or delay the onset of alzheimer's disease and related dementias.


Eligibility criteria:
inclusion criteria: * age 45-69 years * normal cognition (minnesota cognitive acuity scale \> 52) * english language fluency * at least two of the following: i) bmi \> 24.9; ii) systolic blood pressure \> 125 mmhg; iii) ldl cholesterol \> 115 mg/dl; iv) hba1c \> 6.0%; v) at least one apoe ε4 allele; vi) first-degree relative with ad. exclusion criteria: * history of serious mental illness (i.e., schizophrenia, bipolar disorder) * history of neurologic or neurodevelopmental disorder * current alcohol or drug use disorder based on self-report * current enrollment in an ad prevention clinical trial.
molecular and genetic analysis of lung cancer

Conditions: Lung Cancer

Summary: investigators use a genome-wide approach within a case-control design to identify snps that show evidence of association with lung cancer risk and survival.

investigators also investigate how genetic variants may affect cancer treatment, at various stages of disease development, in order to determine prognostic and predictive factors for survival.

Eligibility criteria:
inclusion criteria: * healthy controls: participants without evidence of any cancer * cases: pathology proven primary lung cancer exclusion criteria: * younger than 18 years old
comparison of success rate between distal radial approach and radial approach in stemi

Conditions: Distal Radial Artery Approach; ST Elevation Myocardial Infarction

Summary: st-segment elevation myocardial infarction (stemi) is an emergent disease to treat as soon as possible. 2017 esc guidelines for the management of stemi recommend using radial approach (ra) rather than femoral approach (fa) to reduce mortality and bleeding complications if the operators are expert for ra. recently, ferdinand kiemeneij reported that distal radial approach (dra) could be a feasible and safe route for coronary angiography (cag) and percutaneous coronary intervention (pci) in 70 patients. the right-handed patient could feel more comfortable in left dra than right ra. left dra also could provide a better comfortable position for the operator compared to left ra. distal radial artery is located around the anatomical snuffbox, which doesn't contain nerve and vein beside artery. therefore, the possibility of procedure-related complications such as nerve injury or arteriovenous fistula is very low. also, the superficial location of dra could make easier hemostasis. there were no vascular-related complications from the report of kiemeneij. but, the rate of puncture failure was 11%, which was higher than ra-based study (5.34% in stemi patients of rival trial, 6% in riflesteacs trial and 5.8% in matrix trial). nevertheless, this study was a pilot study with a small number of patients. there is no clinical study to compare the feasibility and safety for cag and pci between dra and ra in patients with stemi. therefore, this study aimed to evaluate whether dra is feasible and safe compared to ra in stemi setting.


Eligibility criteria:
inclusion criteria: * age ≥ 20 years * st-segment elevation myocardial infarction * palpable unilateral distal radial and radial artery exclusion criteria: * cardiogenic shock * thrombolysis before primary percutaneous coronary intervention * inability to obtain written informed consent * patient with ipsilateral arteriovenous fistula * participation in another ongoing clinical trial * pregnancy * expected lifespan \<12 months \* eligible operator criteria * qualified operator who had experienced ≥ 100 cases of distal radial artery puncture

Keywords: distal radial approach st elevation myocardial infarction
risperidone and olanzapine for the schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism

Conditions: Schizophrenia; Extrapyramidal Syndrome

Summary: we initiate a study with research grant from department of health and taoyuan mental hospital and choose risperidone and olanzapine as study medications. we compare the incidence of using anticholinergic drugs in schizophrenic patients of han ethnics with neuroleptic-induced acute dystonia or parkinsonism to test the hypothesis that these two medications have different eps incidence in eps intolerant population.

objective: first generation antipsychotics frequently induced extrapyramidal side effects (eps). second generation antipsychotics were the choices for eps intolerant schizophrenic patients. but which one of second generation antipsychotic was the better choice did not have definitive results. we compared risperidone and olanzapine in schizophrenic patients with acute dystonia or parkinsonism side effects and observed the incidence of needing concomitant anticholinergic drugs. we also collected the data of average dose of risperidone and olanzapine to help the dosing strategy guidelines for eps intolerant schizophrenic patients. method: this randomized, rater-blind, parallel group, flexible dose study enrolled patients from taoyuan mental hospital from july 2000 to july 2003. schizophrenia (dsm-iv) patients who met the research criteria of neuroleptic-induced acute dystonia or parkinsonism research criteria of dsm-iv and greater than moderate severity (\>4) of global impression of extrapyramidal syndrome rating scale (esrs). 70 patients were random assignment to risperidone or olanzapine for 8 weeks. the primary outcome was to compare the incidence of concomitant anticholinergic drugs.

Eligibility criteria:
inclusion criteria: * age of 18-65 y/o; * female patients did not have pregnancy plans and must agree to use reliable pregnancy prevention methods if during childbearing age; * meet schizophrenia criteria of dsm-iv; * fulfill dsm-iv neuroleptic-induced acute dystonia or parkinsonism research criteria, the severity of acute dystonia or parkinsonism was greater than moderate degree (\>4) assessed by global impression of extrapyramidal system rating scale (item 43 and 44 of esrs); * patients or legal responsible people agree to join study and sign informed consent exclusion criteria: * had other axis i diagnosis of dsm-iv; * unstable major systemic diseases; * had neurological disorder influenced to eps assessment; * substance abuse or dependence other then coffee or tobacco within 6 months before study

Keywords: schizophrenia, eps, risperidone, olanzapine
a research study to assess if cc-930 is safe in treating subjects with discoid lupus erythematosus

Conditions: Discoid Lupus

Summary: the purpose of the study is to assess if cc-930 is safe and tolerable in treating subjects with discoid lupus erythematosus. pharmacokinetic and pharmacodynamics will also be evaluated.

enrollment will occur in sequential, ascending, dose-sequence design, where a higher cc-930 dose level and longer duration of dosing (cohort) will not be initiated until supportive safety profile is demonstrated in the preceding cohort. there will be 4 cohorts as described here; cohort 1: 25 mg once daily for 4 weeks cohort 2: 50 mg once daily for 4 weeks cohort 3: 100 mg once daily for 6 weeks cohort 4: 100 mg twice daily for 6 weeks

Eligibility criteria:
inclusion criteria: 1. male or female with clinical diagnosis of discoid lupus erythematosus (dle) aged 18 to 64 years 2. good health as assessed by investigator 3. dle for at least 16 weeks prior to screening and consistent histological findings. 4. considered a candidate for systemic therapy. may be naïve to systemic therapy or experiencing incomplete or refractory disease on systemic therapy. 5. cutaneous lupus area and severity index (clasi) activity score of at least 10, as determined by investigator. 6. subjects using hydroxychloroquine, chloroquine, or quinacrine must have documented ophthalmologic exam within 24 weeks of baseline visit. 7. must meet laboratory criteria for white blood cells, absolute neutrophils, platelets, serum creatinine, aspartate aminotransferase (ast), alanine aminotransferase (alt), bilirubin and hemoglobin. 8. subjects, male and female, must agree to strict pregnancy prevention and testing requirements. exclusion criteria: 1. significant illnesses as determined by physician. 2. history of significant cardiac conditions or interventions within prior 6 months including abnormal electrocardiogram (ecg) findings. 3. systolic blood pressure \ 150 mm hg 4. diastolic blood pressure \> 90 mm hg. 5. pregnancy or breast feeding. 6. other dermatological conditions that would interfere with clasi activity score assessments. 7. history of or active; malignancy, human immunodeficiency virus (hiv), tuberculosis infection, other mycobacterial infection, congenital or acquired immunodeficiency, hepatitis b and c. 8. clinically significant abnormality on chest x-ray. 9. participation in multiple cc-930 cohorts. 10. history of thrombolytic event. 11. positive tests for lupus anticoagulant, anti-cardiolipin antibodies, antibodies to beta-2 glycoprotein 1 or phosphatidylserine at screening. 12. positive antineutrophilic cytoplasmic antibody (anca) at screening. 13. diagnosis of sle. 14. presence or history of medically significant systemic lupus erythematosis (sle) or lupus erythematosis (le) comorbidities. 15. history of seizures, chorea or psychosis. 16. presence or history of persistent proteinuria or urinary cellular casts. 17. prohibited prior or concomitant medications.

Keywords: lupus discoid lupus dle cutaneous lupus
comparison between cobalt-chromium partial dentures and thermoplastic partial dentures

Conditions: Jaw, Edentulous, Partially

Summary: the cobalt-chromium (cocr) partial denture has been made for a long period. it respects biomechanical principles, providing harmony between mechanical and biological activities. the fundamental principles of biomechanics applied in the manufacture of steel structure are: retention, reciprocity, attachment and stability. to get the proper planning, we need to assess the dental support system, with its qualitative and quantitative values. but conventional dentures has a inherent problem which is the metallic elements apparent and in some cases the stiffness of the component support elements that generates stress. the thermoplastic partial dentures increase aesthetics in replacement of metal structures in oral rehabilitation. so many treatments are being done in everyday practice without a defined concept on various aspects of its construction and oral applicability. this trial aims to assess the basic parameters of both dentures in: nutrition, speech therapy, chewing force, chewing efficiency and quality of life. 60 years old or older patients who require removable prosthesis. these will be randomly selected for the fabrication and installation of removable partial dentures (gold standard - control group - cocr partial denture) and thermoplastic partial denture(experimental group). before beginning the work, selected patients will make some preliminary tests such as controlling the individual condition, they are: * three questionnaires: * instrument for assessing quality of life related to oral health, gohai - general oral health assessment index of atchinson \& dolan * instrument for assessing the social and economic profile of abep (brazilian association of research companies) cceb 2011; * instrument for assessing cognitive condition mini-mental; * speech evaluation * nutritional assessment; * evaluation of masticatory efficiency and * chewing strength. after preliminary assessments patients will be subjected to treatments for manufacture of partial dentures. after the installation (end of the technical construction of the dentures) and the adjustments appointment the tests will be repeated and in successive control periods of 3 months, 6 months, 12 months, 18 months and 24 months respectively, when the tests will do again now to see if there was a change in the initial condition.


Eligibility criteria:
inclusion criteria: 60 years old or older patient with partial edentulous jaws with indication of removable partial denture exclusion criteria: patient younger than 60 years patient with edentulous mouth

Keywords: dental prosthesis dental prosthesis design
one trial of jcxh-211 intratumoral injection combined with anti-pd-1 antibody in patients with malignant solid tumors

Conditions: Malignant Solid Tumors

Summary: this is an open-label, dose-escalation and dose-expansion phase i clinical study divided into phase ia and phase ib to evaluate the safety and tolerability of jcxh-211 combined with anti-pd-1 antibody in patients with malignant solid tumors.

phase ia: dose escalation study of intratumoral injection of jcxh-211 combined with anti-pd-1 antibody iv infusion a dose escalation study of intratumoral injection of jcxh-211 combined with anti-pd-1 antibody iv infusion will be planned in 2 dose groups . three to six patients will be enrolled in each dose group. phase ib:dose expansion study of jcxh-211 combined with anti-pd-1 antibody in this part of the study, the sponsor and investigator select the optimal dose based on the safety, pk, pd and preliminary efficacy results of the dose escalation phase, and select 1 to 2 of the tumors for jcxh-211 combined with anti-pd-1 antibody dose expansion study with reference to the approved indications of anti-pd-1 antibody (toripalimab ) in china, and planned to enroll 15 to 30 patients in each cohort of combination therapy. tumor response assessments will be performed using recist1.1 and irecist at the end of study treatment/early withdrawal visit and every 6 weeks during treatment. all patients will be followed for safety and survival. the data cut-off date for study is defined as 6 months after the last patient is enrolled.

Eligibility criteria:
inclusion criteria: 1. male or female patients, aged 18 to 75 years; 2. patients with malignant solid tumors confirmed by pathology and/or cytology who have progressed or are intolerant to standard treatment (except best supportive care); including patients who have received prior anti-pd-1 antibody therapy; patients who have been approved as eligible for toripalimab: 3. general condition score ecog 0 \~ 1; 4. expected survival of more than 3 months; exclusion criteria: 1. known or suspected allergy to the ingredients of the study drug or its analogues; allergic history to another monoclonal antibody; 2. patients who have previously received il-12 therapy (alone or as part of a treatment regimen), except those who have participated in tolerance to a single intratumoral injection; 3. patients who have previously received treatment with anti-pd-1, anti-pd-l1, or anti-pd-l2 agents, or have received treatment directed at another stimulatory or coinhibitory t-cell receptor (e.g., ctla-4, ox-40, cd137), and discontinued treatment due to grade 3 or higher immune-related adverse events (iraes);
preventing injury in elite orienteerers

Conditions: Lower Extremity Injury

Summary: the aim of this study is to investigate the effect a specific exercise program on the incidence of injuries in the lower extremity. 72 elite orienteerers, aged 18-40 years, are allocated to an intervention or control group. the intervention group performs four specific exercises, four times a week (10 minutes per session) in conjunction with normal training. injury data are collected every second week using valid injury questionnaire distributed by text messages over 14 weeks. primary outcome is number of substantial injuries in the lower extremity. secondary outcomes are incidence of ankle sprains and the average substantial injury prevalence across the 10 weeks.

the high physical load associated with running through uneven terrain contributes to that orienteerers are exposed to high injury risk, where the majority of injuries located in the lower extremities. specific training programmes have been effective at reducing injury risk in sports. yet, not trial has been conducted in elite orienteering. the aim of this study is to investigate the effect a specific exercise program on the incidence of injuries in the lower extremity. 72 elite orienteerers, aged 18-40 years, are allocated to an intervention or control group. the intervention group performs four specific exercises, with three difficult levels intensified every second week over the first four weeks, targeting strength, flexibility and coordination of the lower extremity. the exercises are completed four times a week (10 minutes per session) in conjunction with normal training. injury data are collected every second week using valid injury questionnaire distributed by text messages over 14 weeks. primary outcome is number of substantial injuries in the lower extremity. secondary outcomes are incidence of ankle sprains and the average substantial injury prevalence across the 10 weeks. participants will be recruited in january-february 2018. the intervention starts in february 2018 and data collection will be completed in june 2018. data analyses are expected to be completed in october-november 2018. due to high injury risk and lack of injury prevention trials in orienteering, a rct investigating the effect of a specific exercise program on the incidence of injuries in the lower extremity, is warranted. the results of this trial will be beneficial to orienteerers, clubs, federations and increase our understanding on how lower extremity injuries can be prevented in a physically challenging sport.

Eligibility criteria:
inclusion criteria: adult elite orienteerers aged 18-40 years participating in the highest national orienteering league (swedish league) participant inclusion criteria - age group: adult participant inclusion criteria - gender: both exclusion criteria: injured adult elite orienteerers not able to perform baseline tests

Keywords: elite orienteering